XAIR vs. CTSO, HYPR, EDAP, ICCM, MLSS, APT, CTCX, INO, DXR, and ECOR
Should you be buying Beyond Air stock or one of its competitors? The main competitors of Beyond Air include Cytosorbents (CTSO), Hyperfine (HYPR), Edap Tms (EDAP), IceCure Medical (ICCM), Milestone Scientific (MLSS), Alpha Pro Tech (APT), Carmell (CTCX), Inovio Pharmaceuticals (INO), Daxor (DXR), and electroCore (ECOR). These companies are all part of the "medical equipment" industry.
Beyond Air vs. Its Competitors
Cytosorbents (NASDAQ:CTSO) and Beyond Air (NASDAQ:XAIR) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, media sentiment, analyst recommendations, dividends, profitability, valuation, risk and earnings.
Cytosorbents has a net margin of -41.77% compared to Beyond Air's net margin of -1,258.46%. Cytosorbents' return on equity of -105.04% beat Beyond Air's return on equity.
Cytosorbents has a beta of 1.19, meaning that its share price is 19% more volatile than the S&P 500. Comparatively, Beyond Air has a beta of 0.22, meaning that its share price is 78% less volatile than the S&P 500.
32.9% of Cytosorbents shares are held by institutional investors. Comparatively, 31.5% of Beyond Air shares are held by institutional investors. 7.3% of Cytosorbents shares are held by company insiders. Comparatively, 19.4% of Beyond Air shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.
In the previous week, Cytosorbents had 1 more articles in the media than Beyond Air. MarketBeat recorded 3 mentions for Cytosorbents and 2 mentions for Beyond Air. Beyond Air's average media sentiment score of 1.32 beat Cytosorbents' score of 0.08 indicating that Beyond Air is being referred to more favorably in the news media.
Cytosorbents has higher revenue and earnings than Beyond Air. Cytosorbents is trading at a lower price-to-earnings ratio than Beyond Air, indicating that it is currently the more affordable of the two stocks.
Cytosorbents currently has a consensus price target of $5.50, suggesting a potential upside of 382.46%. Beyond Air has a consensus price target of $1.50, suggesting a potential upside of 669.23%. Given Beyond Air's stronger consensus rating and higher possible upside, analysts clearly believe Beyond Air is more favorable than Cytosorbents.
Summary
Cytosorbents beats Beyond Air on 9 of the 16 factors compared between the two stocks.
Get Beyond Air News Delivered to You Automatically
Sign up to receive the latest news and ratings for XAIR and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding XAIR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Beyond Air Competitors List
Related Companies and Tools
This page (NASDAQ:XAIR) was last updated on 7/10/2025 by MarketBeat.com Staff
